Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 4/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | TRPM7 | Q96QT4 | 1/20 | 0.49 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | OSBP | P22059 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24075655 | 0.88 | MEN1 (0.49) | PTGESALOX5PTGS1PTGS2MAOB | |
| SCHEMBL24074938 | 0.88 | PTGES (0.57) | PTGESALOX5PTGS1PTGS2APP | |
| SCHEMBL31580515 | 0.85 | MEN1 (0.49) | PTGESALOX5PTGS1PTGS2MAOB | |
| SCHEMBL24075568 | 0.84 | ALOX5 (0.77) | PTGESALOX5PTGS1PTGS2APP | |
| SCHEMBL29377594 | 0.79 | FASN (0.46) | PTGESALOX5PTGS1PTGS2APP | |
| SCHEMBL24074934 | 0.77 | PTGES (0.60) | PTGESALOX5PTGS1PTGS2APP | |
| SCHEMBL24075656 | 0.75 | HIF1A (0.56) | PTGESALOX5MAOB | |
| SCHEMBL24075662 | 0.74 | PTGES (0.72) | PTGESALOX5PTGS1PTGS2APP | |
| SCHEMBL2723348 | 0.73 | PTGES (0.61) | PTGESALOX5PTGS1PTGS2APP | |
| SCHEMBL24075565 | 0.72 | FFAR1 (0.59) | PTGESALOX5PTGS1PTGS2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795127-B2 | Processes for the preparation of ortho-allylated hydroxy aryl compounds | MCMASTER UNIVERSITY (CA) | 2023-10-24 | — | — | US | disclosed |
| US-11795127-B2 | Processes for the preparation of ortho-allylated hydroxy aryl compounds | MCMASTER UNIVERSITY (CA) | 2023-10-24 | — | — | US | disclosed |
| US-20230113567-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | MCMASTER UNIVERSITY (CA) | 2023-04-13 | — | — | US | disclosed |
| US-20210380513-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | MCMASTER UNIVERSITY (CA) | 2021-12-09 | — | — | US | disclosed |
| WO-2021237371-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | MCMASTER UNIVERSITY (CA) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113567-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | ADH1A, ADH1C, AHR | PTGES 1307/4885ALOX5 18/4885PTGS1 1779/4885 |
| US-20210380513-A1 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | ADH1A, ADH1C, AHR | PTGES 1307/4885ALOX5 18/4885PTGS1 1779/4885 |
| US-11795127-B2 | Processes for the preparation of ortho-allylated hydroxy aryl compounds | ADH1A, ADH1C, AHR | PTGES 1307/4885ALOX5 18/4885PTGS1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.